Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)

NCT00586105 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)

Sponsor

Bayer